Literature DB >> 7714226

Acute and subchronic effects of nefazodone and imipramine on highway driving, cognitive functions, and daytime sleepiness in healthy adult and elderly subjects.

M W van Laar1, A P van Willigenburg, E R Volkerts.   

Abstract

The acute and subchronic effects of two dosages of a new serotonergic antidepressant, nefazodone, and those of the tricyclic imipramine were examined in a double-blind, crossover, placebo-controlled study. Twenty-four healthy subjects from two age groups (12 adults and 12 elderly from both sexes) received the four treatments (nefazodone, 100 and 200 mg twice daily; imipramine, 50 mg twice daily; and placebo) for 7 days with a 7-day washout period. Measurements were performed after the morning doses on day 1 and day 7. These included a standard over-the-road highway driving test, a psychomotor test battery, and sleep latency tests. Blood samples were taken on both days and analyzed to determine concentrations of parent drugs and their major metabolites. The main results showed that the reference drug, imipramine, had a detrimental effect after a single dose on lateral position control in the driving test, primarily in the adult group, that diminished after repeated dosing. Minor impairment on psychomotor test performance was found with both days. On the other hand, a single administration of both doses of nefazodone did not impair highway driving performance (even showed some improvement) and had no or only minor effects on psychomotor performance. After repeated dosing, nefazodone 200 mg twice daily (but not the 100-mg dose) produced slight impairment of lateral position control; dose-related impairment of cognitive and memory functions was found. The effects of nefazodone were generally in the same direction in both age groups. Significant correlations were found between steady-state concentrations of nefazodone in plasma (200-mg, twice-daily condition) as well as imipramine, and reaction time changes in a memory scanning task. Neither drug appeared to induce daytime sleepiness as measured by the sleep latency tests.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7714226     DOI: 10.1097/00004714-199502000-00006

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN: 0271-0749            Impact factor:   3.153


  13 in total

Review 1.  Pharmacologic treatment of depression in late life.

Authors:  A J Flint
Journal:  CMAJ       Date:  1997-10-15       Impact factor: 8.262

Review 2.  Pathological laughing and crying : epidemiology, pathophysiology and treatment.

Authors:  Hal S Wortzel; Timothy J Oster; C Alan Anderson; David B Arciniegas
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

3.  Nefazodone. Psychomotor and cognitive effects.

Authors:  M W van Laar
Journal:  Drugs       Date:  1997-07       Impact factor: 9.546

Review 4.  Potentially Driver-Impairing Medications: Risks and Strategies for Injury Prevention.

Authors:  Timothy Ivers; Nicole D White
Journal:  Am J Lifestyle Med       Date:  2016-01-13

Review 5.  A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.

Authors:  Cara Tannenbaum; Amélie Paquette; Sarah Hilmer; Jayna Holroyd-Leduc; Ryan Carnahan
Journal:  Drugs Aging       Date:  2012-08-01       Impact factor: 3.923

Review 6.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

7.  Depression, antidepressants, and accidents.

Authors:  J G Edwards
Journal:  BMJ       Date:  1995-10-07

Review 8.  Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects.

Authors:  G J H Dumont; S J de Visser; A F Cohen; J M A van Gerven
Journal:  Br J Clin Pharmacol       Date:  2005-05       Impact factor: 4.335

Review 9.  Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression.

Authors:  R Davis; R Whittington; H M Bryson
Journal:  Drugs       Date:  1997-04       Impact factor: 9.546

Review 10.  Choosing appropriate antidepressant therapy in the elderly. A risk-benefit assessment of available agents.

Authors:  A J Flint
Journal:  Drugs Aging       Date:  1998-10       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.